Maynard Um
-
-
-
-
-
-
-
Lucid Capital Markets Starts Acumen Pharmaceuticals, Inc. (ABOS) at Buy
-
-
-
-
-
-
-
Acumen Pharmaceuticals, Inc (ABOS) Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Acumen Pharmaceuticals, Inc. (ABOS)
-
-
-
-
-
-
401,069 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

